Literature DB >> 9655703

Additivity of protein and nonprotein inhibitors of lung surfactant activity.

Z Wang1, R H Notter.   

Abstract

This study examined the degree of additivity of several physiologically relevant protein and nonprotein inhibitors in impairing the surface activity of whole and extracted calf lung surfactant (LS and CLSE) on a pulsating bubble apparatus at 37 degrees C. Inhibitors investigated were albumin, hemoglobin, C16:0 and C18:1 lysophosphatidylcholine (LPC), oleic acid (OA), palmitoleic acid (PA), arachidonic acid (AA), and mixed red blood cell membrane lipids (RBCML). In the absence of inhibitors, LS (0.5 mg/ml) and CLSE (0.75 mg/ml) reached minimum surface tensions < 1 mN/m within 5 min of bubble pulsation (20 cycles/min, 50% area compression). Each inhibitor acting alone was able to reduce the surface activity of LS and CLSE, either raising minimum surface tension or increasing the time course of surface tension lowering or both. Several combinations of inhibitors exhibited additivity in impairing LS or CLSE activity at a lower concentration in mixtures than when present alone (albumin plus either C16:0 LPC, C18:1 LPC, or RBCML; hemoglobin plus either C16:0 LPC, C18:1 LPC, RBCML, PA, OA, or AA). The degree of additivity, however, was typically small in terms of the magnitude of reduction in inhibitor concentration or the rise in minimum surface tension relative to the effects of the most severe single inhibitor present. Substantial synergy was not found for any of the combinations of protein and nonprotein inhibitors investigated. Mixtures of albumin with PA or AA actually had a reduced inhibitory effect on LS and CLSE activity compared with the free fatty acids alone, apparently because of albumin binding of these molecules. In all cases, the detrimental effects of mixed inhibitors on LS and CLSE activity were reversed at increased surfactant concentration. These results indicate that surfactant dysfunction in acute respiratory distress syndrome (ARDS) could be increased in severity by interactions between some inhibitory substances, but that supplementation with exogenous CLSE would be effective in reversing inactivation by the mixtures of blood proteins, membrane lipids, and fatty acids studied.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655703     DOI: 10.1164/ajrccm.158.1.9709041

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  16 in total

1.  Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia.

Authors:  T W Wright; R H Notter; Z Wang; A G Harmsen; F Gigliotti
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

Review 2.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

3.  A non-BRICHOS surfactant protein c mutation disrupts epithelial cell function and intercellular signaling.

Authors:  Markus Woischnik; Christiane Sparr; Sunčana Kern; Tobias Thurm; Andreas Hector; Dominik Hartl; Gerhard Liebisch; Surafel Mulugeta; Michael F Beers; Gerd Schmitz; Matthias Griese
Journal:  BMC Cell Biol       Date:  2010-11-20       Impact factor: 4.241

Review 4.  Surfactant for pediatric acute lung injury.

Authors:  Douglas F Willson; Patricia R Chess; Robert H Notter
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

5.  Activity and inhibition resistance of a phospholipase-resistant synthetic surfactant in rat lungs.

Authors:  Zhengdong Wang; Yusuo Chang; Adrian L Schwan; Robert H Notter
Journal:  Am J Respir Cell Mol Biol       Date:  2007-06-07       Impact factor: 6.914

6.  Surfactant dysfunction in lung contusion with and without superimposed gastric aspiration in a rat model.

Authors:  Krishnan Raghavendran; Bruce A Davidson; Paul R Knight; Zhengdong Wang; Jadwiga Helinski; Patricia R Chess; Robert H Notter
Journal:  Shock       Date:  2008-11       Impact factor: 3.454

7.  Increased phospholipase A2 and lyso-phosphatidylcholine levels are associated with surfactant dysfunction in lung contusion injury in mice.

Authors:  David Machado-Aranda; Zhengdong Wang; Bi Yu; M V Suresh; Robert H Notter; Krishnan Raghavendran
Journal:  Surgery       Date:  2012-07-31       Impact factor: 3.982

8.  The surfactant protein C mutation A116D alters cellular processing, stress tolerance, surfactant lipid composition, and immune cell activation.

Authors:  Ralf Zarbock; Markus Woischnik; Christiane Sparr; Tobias Thurm; Sunčana Kern; Eva Kaltenborn; Andreas Hector; Dominik Hartl; Gerhard Liebisch; Gerd Schmitz; Matthias Griese
Journal:  BMC Pulm Med       Date:  2012-03-29       Impact factor: 3.317

Review 9.  Lung surfactant in subacute pulmonary disease.

Authors:  Gehan Devendra; Roger G Spragg
Journal:  Respir Res       Date:  2002-04-04

10.  Dynamic surface activity of a fully synthetic phospholipase-resistant lipid/peptide lung surfactant.

Authors:  Frans J Walther; Alan J Waring; Jose M Hernandez-Juviel; Larry M Gordon; Adrian L Schwan; Chun-Ling Jung; Yusuo Chang; Zhengdong Wang; Robert H Notter
Journal:  PLoS One       Date:  2007-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.